Evidence map›Paper›PMID 37477774›Full record

ArticleStem cell reviews and reports2023

Activation of MG53 Enhances Cell Survival and Engraftment of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Injured Hearts.

Ki Ho Park, Xingyu He, Lin Jiang, Hua Zhu, Jialiang Liang, Yigang Wang, Jianjie Ma

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reviews and reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Ki Ho ParkDivision of Surgical Sciences, Department of Surgery, University of Virginia School of Medicine, Charlottesville, VA, USA. uuh2qa@virginia.edu.
Xingyu HeDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH, USA.
Lin JiangDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH, USA.
Hua ZhuDepartment of Surgery, College of Medicine, The Ohio State University, Columbus, OH, USA.
Jialiang LiangDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH, USA.
Yigang WangDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH, USA. yi-gang.wang@uc.edu.ORCID 0000-0002-0872-1860
Jianjie MaDivision of Surgical Sciences, Department of Surgery, University of Virginia School of Medicine, Charlottesville, VA, USA. qga3zx@virginia.edu.
University of Cincinnati Medical Center · USUniversity of Virginia · USThe Ohio State University · USUniversity of Cincinnati · US

Funding

MG53 function in muscle agingR01AG071676 · NIA · UNIVERSITY OF VIRGINIA · PI Jianjie Ma, Ki Ho Park · 2022 to 2026
$3.1M
Protein therapy to treat virus induced cardiopulmonary injuryR01HL157215 · NHLBI · UNIVERSITY OF VIRGINIA · PI CAI, CHUANXI, MA, JIANJIE · 2022 to 2025
$2.7M
CRISPR-induced cardiovascular progenitor cells to repair myocardial infarctionR01HL157456 · NHLBI · UNIVERSITY OF CINCINNATI · PI LIANG, JIALIANG, WANG, YIGANG · 2021 to 2024
$2.4M
IGF-2R is a new therapeutic target for cardiac ischemia-reperfusion injuryR01HL143490 · NHLBI · UNIVERSITY OF CINCINNATI · PI WANG, YIGANG · 2019 to 2022
$1.6M
Activity effects on Alzheimer neuropathology &dementiaR01AG022439 · NIA · VANDERBILT UNIVERSITY · PI MCDONALD, MICHAEL P · 2003 to 2006
$1.2M
American Heart Association-American Stroke Association 968781NHLBI NIH HHS R01 HL143490NHLBI NIH HHS R01 HL157215NHLBI NIH HHS R01 HL157456NIA NIH HHS R01 AG022439NIA NIH HHS R01 AG071676
6 · The paper itself

Abstract

BACKGROUND AND

objectiveOur previous studies demonstrated that MG53 protein can protect the myocardium, but its use as a therapeutic is challenging due to its short half-life in blood circulation. This study aimed to investigate the cardioprotective role of MG53 on human induced pluripotent stem cell-derived cardiomyocytes (HiPSC-CMs) in the context of myocardial ischemia/reperfusion (I/R).

methodsIn vitro: HiPSC-CMs were transfected with adenoviral MG53 (HiPSC-CMs

resultsMG53 can be expressed in HiPSC-CM

conclusionInducible MG53 expression is a promising approach to enhance cell survival and engraftment of HiPSC-CMs for cardiac repair.

Indexed as

Induced Pluripotent Stem CellsMyocytes, CardiacAnimalsCell SurvivalHumansHydrogen PeroxideIschemiaMembrane ProteinsMiceHydrogen PeroxideMembrane ProteinsMG53 protein, mouseCardiomyocytesDoxycyclineHuman induced pluripotent stem cellsImmunocompromised miceIschemia–reperfusionMG53Myocardial infarction

Identifiers

PMID37477774
PMCPMC10579131
OpenAlexW4384924140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.